Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674986 · ClinicalTrials.gov registry record · NA
A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes
A NA study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- NA
- Development phase
- 522
- Enrollment target
NCT00674986 is a NA study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 522 participants.
The verdict
NCT00674986, a NA study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- NA
- Development phase
- 522 participants
- Enrollment target
Study Summary
This randomized, parallel group study will determine whether the use of episodic, intensive glucose monitoring via the Accu-Chek 360 view blood glucose analysis system has a positive effect on overall glycemic control. Patients will be randomized into either the 'usual care' group, or the 'interventional group' supplemented with the Accu-Chek 360 view blood glucose analysis system. The effect of each treatment regimen on glycemic control will be assessed by measurement of change in baseline HbA1c values at 12 months. The anticipated time on study treatment is 1 year, and the target sample size is 504 individuals.
Interventions
- DEVICE Accu-Chek 360° View Blood Glucose Analysis Tool
- DEVICE Accu-Chek Aviva Glucose Meter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 522 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00674986
The ClinicalTrials.gov registry entry for NCT00674986 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 522 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Accu-Chek 360° View Blood Glucose Analysis Tool is the first listed.
NCT00674986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00674986 about?
NCT00674986 is a clinical study titled "A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes". This randomized, parallel group study will determine whether the use of episodic, intensive glucose monitoring via the Accu-Chek 360 view blood glucose analysis system has a positive effect on overall glycemic control. Patients will be randomized into either the 'usual care' group, or the 'intervent...
What is the current status of trial NCT00674986?
This trial is currently completed. It is a NA study. The enrollment target is 522 participants. The study started on 2008-03. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00674986?
The interventions under investigation include: Accu-Chek 360° View Blood Glucose Analysis Tool (DEVICE), Accu-Chek Aviva Glucose Meter (DEVICE).
Who is sponsoring clinical trial NCT00674986?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.